Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion

Most of SARS-CoV-2 neutralizing antibodies (nAbs) targeted the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein. However, mutations at RBD sequences found in the emerging SARS-CoV-2 variants greatly reduced the effectiveness of nAbs. Here we showed that four nAbs, S2-4D, S2-5D, S2-8...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chia-Jung, Chao, Tai-Ling, Chang, Ting-Yu, Hsiao, Chia-Chun, Lu, De-Chao, Chiang, Yi-Wei, Lai, Guan-Chun, Tsai, Ya-Min, Fang, Jun-Tung, Ieong, Siman, Wang, Jann-Tay, Chang, Sui-Yuan, Chang, Shih-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045258/
https://www.ncbi.nlm.nih.gov/pubmed/35293796
http://dx.doi.org/10.1128/spectrum.01814-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045258/
https://www.ncbi.nlm.nih.gov/pubmed/35293796
http://dx.doi.org/10.1128/spectrum.01814-21

Ejemplares similares